NIKA PHARMACEUTICALS, INC (NIKA): M&A transaction — Nika Pharmaceuticals acquires subsidiary and factory building valued at $2.05M; signs $958K supply agreement

NIKA PHARMACEUTICALS, INC

Acquired 100% of Nika Pharmaceuticals, Ltd. from CEO Dimitar Savov for nominal 5,000 BGN (~$2,800).
Acquisition includes beneficial ownership of a production building and land in Sofia valued at $2,045,209.
Nika Europe, Ltd. signed a GMP vial production line supply agreement with Shanghai Marya for $957,670; down payment of $191,534 paid by CEO personally.
Equipment delivery and installation expected by end of Q4 2024.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NIKA PHARMACEUTICALS, INC completed an acquisition involving Dimitar Slavchev Savov for nominal value of the capital of the company, 5,000 BGN (closed 2024-05-09).

Action: acquisition
Counterparty: Dimitar Slavchev Savov
Consideration: nominal value of the capital of the company, 5,000 BGN
Closing: 2024-05-09

Exact text from the filing

Effective May 9, 2024, Nika Pharmaceuticals, Inc. acquired 100% of Nika Pharmaceuticals, Ltd., a limited liability company registered in Bulgaria with UIC: 175420503. The ownership was acquired from Dimitar SlavchevSavov who is an officer, director and majority shareholder of Nika Pharmaceuticals, Inc. and general manager of Nika Pharmaceuticals, Ltd. for the nominal value of the capital of the company, 5,000 BGN.

View on SEC.gov

Browse all m&a transactions →

NIKA PHARMACEUTICALS, INC filing history →

Source: SEC EDGAR

accession 0001826466-24-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.